News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 15, 2023
Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt PHOENIX, Nov. 15, 2023 /PRNewswire/ -- Creative Medical...
-
Oct 10, 2023
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023...
-
Sep 19, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 28, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 12, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 12, 2023
Continued Advancements in Developing Regenerative Therapeutics While Maintaining Strong Financial Position PHOENIX, June 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc....
-
Jun 9, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
May 31, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
May 22, 2023
Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders PHOENIX, May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical...
-
May 18, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Apr 12, 2023
-- One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes -- PHOENIX, April 12, 2023 /PRNewswire/ --...
-
Apr 4, 2023Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of...
-
Mar 23, 2023
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics,...
-
Mar 21, 2023
Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOENIX, March 21, 2023 /PRNewswire/ -- Creative...
-
Feb 8, 2023
Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX,...
-
Nov 3, 2022
AlloStem™ represents the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX, Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology...
-
Oct 20, 2022
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics,...
-
Sep 26, 2022
--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX, Sept....
-
Jul 28, 2022
Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian Insufficiency PHOENIX, July 28, 2022...
-
Jun 15, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Apr 29, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Apr 20, 2022
-- Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency -- PHOENIX, April 20, 2022 /PRNewswire/ -- Creative Medical Technology...
-
Apr 12, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 31, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 23, 2022
--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX, March 23, 2022...
-
Mar 10, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 8, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 2, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Dec 3, 2021
Creative Medical Technology Holdings, Inc. (the "Company") (NASDAQ: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and...
-
Nov 9, 2021
(OTC-CELZ) Creative Medical Technology Holdings, Inc. (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell...
-
Oct 12, 2021Company Achieves Selective Reprogramming of Pathological Autoimmunity
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient...
-
Oct 1, 2021
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called "exosomes" secreted by cells of its MyeloCelz™ platform and...
-
Sep 16, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today...
-
Aug 9, 2021
Creative Medical Technology Holdings, Inc. ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional...
-
Jul 20, 2021Landmark Patent Containing Over 1000 Claims Filed
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today the launching of its second Regenerative Immunology product, MyeloCelz™. In contrast to the Company's ImmCelz™ product,...
-
Jun 22, 2021Courtney Bartlett DNP, ACNP-BC, RNFA to Lead Clinical Translation of Company's Regenerative Immunotherapy Pipeline
(OTC-CELZ) Creative Medical Technology Holdings announced today recruitment of Dr. Courtney Bartlett to lead clinical development of the Company's pipeline of therapeutic products. Dr. Bartlett...
-
Jun 17, 2021
Creative Medical Technology Holdings, Inc. (OTC - CELZ), announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit today Thursday, June 17, 2021 at...
-
Jun 9, 2021Clinical Stage Regenerative Immunotherapy Company Optimizes Treatment for Diabetes as it Prepares for Additional Investigational New Drug Application
Creative Medical Technology Holdings, trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with new data indicating that the Company's ImmCelz®...
-
May 24, 2021Clinical Stage Biotechnology Company Reports Patent Filing based on Preclinical Data using "Regenerative Immunotherapy" Approach
Creative Medical Technology Holdings, trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease. Using the...
-
May 20, 2021Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz® Platform
Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs...
-
May 14, 2021FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke TreatmentFDA Responds to Company's IND #27375 Including Pharmacology, Manufacturing and Clinical Sections
Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for...
-
Mar 23, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 16, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 10, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 4, 2021Commercial Stage Regenerative Medicine Company Expands it's Hold "Ready to Commercialize" Autologous Bone Marrow Procedures
(OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation...
-
Mar 3, 2021
(OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz® Investigational New Drug...
-
Feb 16, 2021Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of...
-
Feb 10, 2021Company Advances Towards Clinical Trial to Address Premature Ovarian Failure Patients
(OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment. OvaStem®, which is...
-
Feb 8, 2021Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz® Regenerative Immunotherapy
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board.
-
Feb 1, 2021Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeutic Protein HGF-1
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant...
-
Jan 27, 2021Clinical Stage Cellular Therapy Company Advances Product Pipeline into Kidney Failure Market
(OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney...
-
Jan 21, 2021Company Aims to Initiate Multiple Clinical Trials Following Filing of First ImmCelz® "Regenerative Immunotherapy" IND
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory Board. Dr. Reznik is a veteran of multiple startups...
-
Jan 20, 2021Breakthrough Gains for Patients in San Antonio, TX - Now Available in Austin, TX
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Urology, Neurology and Orthopedics, today announced...
-
Jan 19, 2021Possibility of Concurrent Immunological Protection with Beta Cell Regeneration Disclosed in Filed Patent Application
(OTC: CELZ) Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes. In a...
-
Jan 12, 2021Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Cell Therapy
(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to...
-
Jan 6, 2021Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell
Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical...
-
Dec 31, 2020Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart attack. Patent application #63/132472, entitled...
-
Dec 29, 2020Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon...
-
Dec 22, 2020Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifying one of the primary mechanisms of action of its ImmCelz® product in the treatment of stroke. The Company...
-
Dec 16, 2020Company Plans to Leverage Existing AmnioStem® Expertise for Novel Approach to Protecting and Regenerating Injured Brains
Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz® cell based immunotherapy for treatment of stroke. In...
-
Dec 10, 2020Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy
Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company's ImmCelz ® product at generating...
-
Sep 29, 2020Commercial Stage Stem Cell Company Achieves Selective Reprogramming of Pathological Autoimmunity
(OTC-CELZ) -- Creative Medical Technology Holdings announced today proof of concept studies demonstrating efficacy of its ImmCelz ® immunotherapy product in the collage induced model of...
-
Sep 24, 2020
(OTC-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities. CaverStemR: Recruitment and training of physicians on the CaverStemR program for the...
-
Sep 8, 2020Commercial Stage Stem Cell Company Receives Second Patent Issuance Covering Cell Therapies for Disc Inflammation and Degeneration
(OTC – CELZ) -- Creative Medical Technology Holdings Inc. announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office for its patent application,...
-
Aug 20, 2020New Data Supports Current Push for FDA Clearance of Universal Donor Amniotic Fluid Derived Stem Cell Product
Creative Medical Technology Holdings Inc., trading under the ticker symbol CELZ, announced today new data demonstrating effective suppression of stroke associated pathological molecules by...
-
Jul 9, 2020Company Completes Critical Milestone in Development of "Universal Donor" Stem Cell Therapy for Stroke
(OTC-CELZ) Creative Medical Technology Holdings announced today completion of preclinical studies assessing the anti-inflammatory and neuroregenerative activities of AmnioStem™. These studies...
-
Apr 20, 2020Broad Claims Cover Entire Class of Adult Stem Cells for Treatment of Ovarian Failure
Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and...
-
Mar 11, 2020Clinical Stage Adult Stem Cell Therapy Company Discovers New Way to Stop Immune Diseases without Immune Suppression
Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™"....
-
Feb 13, 2020
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Orthopedics and Neurology using adult stem cell treatments, today...
-
Jan 15, 2020
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...
-
Oct 17, 2019
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...
-
Oct 10, 2019
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today provided...
-
Sep 11, 2019Fully integrated campaign expected to drive 6M+ impressions and over 20,000 entries in promotion to provide a complimentary CaverStem® procedure performed by Dr. Scott Sanderson, MD at one of the newest CaverStem® Centers of Excellence: Elite Health Hawaii
Creative Medical Technology Holdings (OTC-CELZ) reported today it has signed an agreement with Edge Media Network to introduce CaverStem® to their community in an integrated campaign spanning...
-
Sep 4, 2019Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be Described in Peer Reviewed Paper
Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem®...
-
Aug 5, 2019OTCQB Status and Accelerating Adoption
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading clinical-stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...
-
Jun 20, 2019General corporate updates and plans for second half of 2019
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ), a leading commercial stage biotechnology company focused on Urology, Orthopedics and Neurology using stem cell treatments, today announced...
-
May 6, 2019
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today coverage of its patented CaverStem ® technology for treatment of erectile dysfunction using the patient's own...
-
Apr 30, 2019
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: As we are releasing updates on a regular basis, we will only cover new activities. The absence...
-
Mar 28, 2019
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: CaverStem™ domestic activities: As previously reported, we are continuing marketing to...
-
Feb 12, 2019
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of it's activities: This update addresses the goals set for Q1 2019 with regard to the ongoing commercialization...
-
Dec 27, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: As we end 2018 we look forward to continuing to reach multiple milestones in 2019. CaverStemTM...
-
Nov 14, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: The company has timely filed its 10Q on 11-14-18, contained in the 10Q is predominantly...
-
Nov 6, 2018
Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of the Brand Building of its CaverStemTM technology, it has awarded a contract to...
-
Oct 17, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: Creative Medical Health, Inc. shall convert $100,000.00 of deferred management compensation to...
-
Sep 24, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its progress: Debt: We have entered into an agreement with three institutional investors in order to wrap up...
-
Sep 4, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities. CaverStemTM: Domestic recruitment, vetting and training of physicians on the CaverStemTM...
-
Aug 14, 2018
(OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities. Debt: Since our last 8k on debt reduction an additional $268,858.00 has been...
-
Jul 19, 2018
Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that its subsidiary Caverstem International LLC has signed an exclusive contract with Promo Med Russia for the...
-
Jul 6, 2018Company Sees Possible Access to AmnioStemTM for Cancer Patients under "Right to Try" Law
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-licensing of patent application...
-
Jun 19, 2018Subsidiary to concentrate on International Erectile Dysfunction Market
Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CaverStem International LLC, a majority owned subsidiary focused on commercializing stem cell therapy for...
-
May 30, 2018
Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that Gary Mells has been hired to lead the CaverStem™ marketing and sales division of the company. "Mr....
-
May 23, 2018Dr. Alexander Gershman Discusses Positive Outcomes in Initial Erectile Dysfunction Patients Who Received Their Own Bone Marrow Stem Cells
Creative Medical Technology Holdings (OTCQB:CELZ) announced today completion of its 3 day exhibition at the American Urology Association (AUA) meeting. The Company's presentations where delivered...
-
May 8, 2018
Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversing natural aging....
-
May 8, 2018
Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that Dr. Alexander Gershman will attend the AUA conference on May 19 th and 20th with Creative Medical...
-
Apr 30, 2018
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that debt to two lenders in the amount of $163,000.00 has been retired. As previously announced Creative Medical Technology...
-
Apr 23, 2018
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that additional debt in the amount of $332,000.00 has been extinguished. As previously announced Creative Medical Technology...
-
Apr 12, 2018The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today it will be giving the Keynote Address at the Veltmeyer Health Care Innovations Symposium April 12 th, 2018 in San Diego, CA....
-
Apr 12, 2018
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today that debt to affiliate company Creative Medical Health, Inc. in the amount of $136,003.00 is being converted to restricted...
-
Apr 4, 2018New Data Opens Door to Addressing Multi-Billion Dollar Autoimmune Market
Creative Medical Technology Holdings (OTCQB: CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with...
-
Mar 27, 2018
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that debt from four early round lenders totaling $255,000.00 of principal has been extinguished. As with many small...